Method for preconception preparation in early recurrent miscarriage
SUBSTANCE: invention refers to medicine, namely to obstetrics and gynaecology, and may be used for preconception preparation in early recurrent miscarriage caused by chronic genital inflammation or inflammatory hormonal ovarian insufficiency. That is ensured by 12 intravaginal introductions of disposable injectors with Dead sea mud gel as a therapeutic agent daily for 30 minutes within one therapeutic course upon completion of the anti-inflammatory treatment following the early miscarriage.
EFFECT: invention provides 50% higher safety and effectiveness of preconception preparation in the given group of patients.
The invention relates to medicine, namely to obstetrics and gynecology, may be used as pregravidarnoy preparation for miscarriage in the early weeks of gestation due to chronic inflammation of the genitals or failure of hormonal function of ovaries inflammatory Genesis.
Infectious cause in recent years has identified as one of the main causes of spontaneous and recurrent miscarriage. Long, often asymptomatic persistence of infectious agents in the endometrium leads to pronounced changes in the fabric structure, the receptor apparatus. Chronic endometritis broken processes implantation, placentation, normal pregnancy, leading to its early losses. For miscarriage chronic endometritis reveal more than 70% of cases .
Chronic endometritis is one of the reasons for the formation of luteal insufficiency (NLF). Results hormonal tests indicate a defective luteal phase of the cycle, 40% of women with recurrent pregnancy loss pregnancy and regular rhythm of menstruation. Failure of the second phase of the menstrual cycle often accompany: disorders of growth and full maturation of follicles; defective ovulation; pathology yellow body. N is the background of what is happening hormonal changes disrupted the structure of the endometrium, what ultimately prevents implantation of the fertilized ovum and the normal development of pregnancy and impaired function luteum, which secretes insufficient progesterone is the cause of spontaneous miscarriage in early pregnancy [2, 6].
Within pregravidarnoy preparation for miscarriage due to chronic inflammation of the genitals or failure of hormonal function of ovaries inflammatory Genesis traditionally provide medical therapy of chronic endometritis and normalization of hormonal status. Treatment includes: antibacterial, antimycotic, antiviral therapy, systemic enzyme therapy, immunomodulators, restoration of normal biocenosis. Correction NLF maintained by progesterone [1, 5]. The duration of therapy exceeds 3 months, which requires a lot of care of the patient in the use of drugs and increases the share of financial costs. In addition, the known adverse effects of antibiotic, antimycotic treatments and medications progesterone on liver function that requires monitoring of biochemical parameters of blood.
In recent years, in medicine in General and in gynecology in particular prevailed point of view about the need for reasonable limits on medicamentos the second load on the body of the patient and the wider application of preformed physical factors . Mud, or peloid, is one of the most physiological of natural physical factors .
The objective of the proposed method of treatment of miscarriage in the early weeks of gestation due to chronic inflammation of the genitals or failure of hormonal function of ovaries inflammatory Genesis is to expand the Arsenal of effective and safe methods of non-pharmacological therapy of this pathology.
The essence of the method is the use as a medicinal product pharmaceutical drug therapeutic Dead sea mud (pelotherapy). In the modern view the main therapeutic effect provide chemical and biological components of peloids. High therapeutic activity of the mud of the Dead sea due to its high salinity. Inorganic chemical components absorbed by the mucous membranes, affect numerous receptors and blood vessels, stimulates the microcirculation. Bactericidal effect due to the presence of peloids substances such as bacteriophages and antibiotics. Makeups therapeutic mud biogenic stimulators activate cellular metabolism and regenerative processes . Hormone-like effect explains the positive effects of medicinal mud on the bodies of reprodu the active system (for example, correction luteal insufficiency) [3, 7].
So, according to the proposed method the use of disposable polymer injectors with gel based on Dead sea mud intrawaginalno 12 treatments daily for 30-60 minutes after 7 days after surgical removal of the ovum by a single course in complex treatment of miscarriage in the early weeks of gestation due to chronic inflammation of the genitals or failure of hormonal function of ovaries inflammatory Genesis, increases the effectiveness of therapy up to 50%. Adverse events during treatment gel is not registered (when using hormonal therapy, the duration of treatment is 3 months, possible unwanted side effects: intermenstrual bleeding, dizziness, headache, abnormal liver function).
The efficacy and safety of the developed method of treatment of miscarriage in the early weeks of gestation due to chronic inflammation of the genitals or failure of hormonal function of ovaries inflammatory Genesis confirmed in a randomized clinical trial. Thus, the use of this method of treatment in the complex treatment of miscarriage in the early weeks of gestation due to chronic inflammatory p is ocess genitals or failure of hormonal function of ovaries inflammatory Genesis helps to restore the two-phase cycle in 72.2% of women in control - 27,8%), the normalization of the structure of the endometrium in 60% (in control - 20%)reduction of signs of chronic endometritis to 13.3% (in control - 46,7%), pregnancy within one year - 92,3% (in the control - 42,9%). The results obtained allowed pathogenetically to justify the application of the developed method for the treatment of complex pregravidarnoy preparation for miscarriage in the early weeks of gestation due to chronic inflammation of the genitals or failure of hormonal function of ovaries inflammatory Genesis.
Contraindications to application of the developed method are: General contraindications to sanatorium-resort treatment, acute inflammatory diseases and suppurative processes; all venereal diseases; hypersensitivity to the components of the product; malignant neoplasms and suspicion on them; pregnancy; menstruation .
The developed method intravaginal pelotherapy should be used in combination pregravidarnoy preparation for miscarriage in the early weeks of gestation due to chronic inflammation of the genitals or failure of hormonal function of ovaries inflammatory Genesis, taking into account contraindications.
Patient N., 22 years. Parvovirinae. Installed the automotive technician is C: Incomplete miscarriage at 8 weeks of pregnancy. Bacterial vaginosis. After manual vacuum aspiration residues of the ovum and antibiotic therapy were assigned to a disposable injector with a gel based on Dead sea mud intrawaginalno 12 treatments daily for 30 minutes in one course. 3 months after treatment registered the pregnancy ended urgent delivery.
Patient B., 28 years. Diagnosed with non-developing pregnancy early period. NLF. After surgical removal of the ovum from the 7th day were assigned disposable injectors with gel based on Dead sea mud intrawaginalno 12 treatments daily for 30 minutes in one course. After 3 months showed restoration of two-phase cycle, the normalization of the hormonal status, full secretory transformation of the endometrium. In the next cycle of registered pregnancies ended urgent delivery.
1. Ilizarov N.A. Habitual miscarriage: pathological analysis of the endometrium, clinical features and rationale for the strategy of therapy: author. dis. ... Dr. med. Sciences: 14.03.02, 14.01.01 / Nailsea. - Novosibirsk, 2009. - 47 S.
2. Myskova YOU Restorative therapy after suffering a non-developing pregnancy / Youmaybe., Digimicro // Rus. the honey. Journe. - 2008. - T.16., No. 29. - S-192.
3. Pelotherapy: real possibilities and prospects of application in gynecology / edited Wierzynski. - M.: Mediabar StatusPraesens, 2011. - 8 S.
4. Early pregnancy / edited Wierzynski, Arr. - M.: StatusPraesens, 2009. - 480 S.
5. Manual of outpatient care in obstetrics and gynaecology / edited by V.I. Kulakov, Vinpalace, Wierzynski. - M.: GEOTAR-Media, 2007. - 1030 S.
6. Sidelnikov V.M. Miscarriage: hands. for doctors / Vmesatelistve, Getsuga. - M., 2010. - 536 S.
7. Artymuk, N.V. Intravaginal gel prepared from Dead Sea peloid for treating luteal-phase defect / N.V.Artymuk, .F.Kira, T.A.Kondratieva // J. ofGynecol. and Obstet. - 2010. - Vol.108. - P.72-73.
The way pregravid preparation for miscarriage in the early weeks of gestation due to chronic inflammation of the genitals or failure of hormonal function of ovaries inflammatory Genesis by intravaginal administration of medicinal means, characterized in that as a drug use disposable injectors with gel based on Dead sea mud 12 treatments daily for 30 minutes one course at the end of the main anti-inflammatory treatment after spontaneous abortion in the early stages.
SUBSTANCE: described are novel arylcyclohexyl esters of 5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene derivatives of formula I where R1 is phenyl, optionally substituted with cyano, C1-7-alkyl, halogen-C1-7-alkyl, C1-7-alkoxy or halogen; naphthyl, pyrazinyl or pyridazinyl; pyridinyl, optionally substituted with halogen or C1-7-alkyl, pyrimidinyl, optionally substituted with C1-7-alkyl, R2 is H, C1-8-alkyl, optionally substituted with OH or halogen, -(CH2)q-Ra, where Ra is a 6-member heteroaryl containing one N as a heteroatom, -C(O)-C1-8-alkyl, -C(O)(CH2)qNRiRii, -C(O)O-C1-8-alkyl, -S(O)2-C1-8alkyl, -S(O)2NRiRii, where Ri and Rii are identical and denote C1-8-alkyl; q =1, R3 is Cl or F, pharmaceutically acceptable salts thereof and a pharmaceutical composition containing said compounds.
EFFECT: present compounds are V1a receptor antagonists and can be used in medicine.
21 cl, 111 ex, 10 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, namely pharmaceutical industry, and concerns a composition for preventing or treating a menopause symptom, containing cinnamylic acid, shanzhiside methyl ester or a mixture thereof as an active ingredient.
EFFECT: preparing the pharmaceutical composition for preventing or treating the menopause symptom.
3 cl, 2 ex
SUBSTANCE: present invention relates to organic chemistry and specifically to novel 2,5-dioxo-imidazolidine derivatives of general formula lb , or pharmaceutically acceptable salts and solvates thereof, or solvates of pharmaceutically acceptable salts, where X denotes O; R1 is H; or R1 is selected from C1-C6 alkyl and C1-C6 alkynyl, where the alkyl can optionally be substituted with a cyano group; R2a is selected from H, P(O)(OH)2 and C(O)(CH2)n1C(O)OH; or R2a is selected from -C(O)-C1-C6 alkyl, which is substituted with amino; n1 equals 1 or 2; each R2 and Rc is independently selected from H and C1-C6 alkyl; R3a is H, a halogen atom or cyano; each R3b is independently a halogen atom or cyano; or each R3b is independently C1-C6 alkyl, optionally substituted with three halogen atoms; each R4a and R4b is independently H or a halogen atom; or each R4a and R4b is selected from C1-C6 alkyl, and C1-C6 alkoxy, where the alkyl is substituted with three halogen atoms; R4c is a halogen atom or cyano; and ml equals 0 or 1. The invention also relates to a pharmaceutical composition based on a compound of formula lb and use thereof.
EFFECT: obtaining novel 2,5-dioxo-imidazolidine derivative which modulate androgen receptor activity.
20 cl, 5 tbl, 31 ex
SUBSTANCE: invention refers to medicine, namely obstetrics and gynaecology, and may be used for treating early miscarriage in females with primary hyperprolactinemia. That is ensured by prescribing a sparing regimen combined with the administration of dufaston. It is added with prescribing the preparation dostinex 0.125 mg - 0.250 mg at bedtime to a pregnant woman 1-2 times a week to the 10-12th week of pregnancy.
EFFECT: method provides higher clinical effectiveness, reduced side effects and complications.
SUBSTANCE: invention relates to stable metastin derivatives, having excellent biological activity. The disclosed metastin derivatives improve stability, gelation tendency is reduced, pharmacokinetics are also improved, and an excellent cancer metastasis suppressing activity or a cancer growth suppressing activity is exhibited.
EFFECT: metastin derivatives of the present invention also have a gonadotropic hormone secretion suppressing activity and sex hormone secretion suppressing activity.
5 cl, 4 tbl, 18 ex
SUBSTANCE: invention refers to medicine, namely gynaecology, and is applicable for the purpose of prevention of hormone resistance in endometrial hyperplasia. That is ensured by prescribing a depot synthetic analogue of gonadotrophin releasing hormone by 1 injection on the 1st-2nd day of menstrual cycle once every 28 days. Nine injections in all. It is combined with an oestrogen-gestagen drug by 1 tablet a day starting with the 14th day after the second injection of the gonadotrophin releasing hormone analogue and up to the 28th day after the ninth injection.
EFFECT: method enables prevention of hormone resistance in endometrial hyperplasia.
SUBSTANCE: group of inventions relates to medicine, namely to gynecology, and can be used for syndrome of ovary hyperstimulation, as well as for its prevention in a subject who is under treatment against infertility with gonadotropic hormone. For this purpose composition, which contains quinagolide in pharmaceutically acceptable carrier, is introduced to patient.
EFFECT: introduction of quinagolide, in contrast to other dophamine agonists, ensures high therapeutic efficiency in considerably smaller doses and is quickly excreted from organism, which reduces risk of toxicity for mother and fetus.
16 cl, 3 tbl, 6 ex, 2 dwg
SUBSTANCE: invention relates to 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives of formula I
or pharmaceutically acceptable salts thereof, where R1 denotes (1-6C)alkyl; R2, R3 independently denote halogen, (1-4C)alkoxy; R4 denotes phenyl or a 5-6-member heteroaryl, having one or two heteroatoms selected from nitrogen, oxygen or sulphur, phenyl or said heteroaryl, substituted with R7 and optionally substituted on the (hetero)aromatic ring with one or two substitutes selected from halogen, nitro, trifluoromethyl and (1-4C)alkyl; R7 denotes H, (1-4C)alkylthio, (1-4C)alkylsulphonyl, R8R9-amino, R10R11-aminocarbonyl, R12R13-amino(1-4C)alkylcarbonyl-amino, R14R15-amino(1-4C)alkyl, R16-oxy, R17R18-aminocarbonyl (1-4C)alkoxy, R19-oxy(1-4C)alkyl, R19-oxycarbonyl(1-4C)alkyl, R20R21-aminosulphonyl, R20-oxysulphonyl, aminoiminomethyl, (di)(1-4C)alkylaminoiminomethyl, morpholinyliminomethyl, trifluoromethylsulphonyl; R23-oxycarbonyl, or R23R24-aminocarbonyl; R8 denotes H or (1-4C)alkyl; R9 denotes (1-4C)alkylsulphonyl, (1-6C)alkylcarbonyl, (2-6C)alkenylcarbonyl, (3-6C)cycloalkylcarbonyl, (1-4C)alkoxycarbonyl, (3-4C)alkenyloxycarbonyl, (di)(1-4C)alkylaminocarbonyl, piperazinylcarbonyl, (5-8C)alkyl, (3-6C)cycloalkyl(1-4C)alkyl or phenylcarbonyl, furylcarbonyl, thiophenylsulphonyl, 5-member heteraryl(1-4C)alkyl, having one or two nitrogen atoms, optionally substituted on the heteroaromatic ring with one, two or three substitutes selected from hydroxy, amino, halogen, nitro, trifluoromethyl, (1-4C)alkoxy; R10 denotes H or (1-4C)alkyl; R11 denotes hydroxy(2-4C)alkyl, (1-4C)alkoxy(2-4C)alkyl; R12, R13 independently denote H, (1-6C)alkyl, (3-6C)-cycloalkyl, (1-4C)alkoxy(2-4C)alkyl, (3-6C)cycloalkyl-(1-4C)alkyl, pyrrolidinyl(1-4C)alkyl, amino(2-4C)alkyl, (di)(1-4C)-alkylamino(2-4C)alkyl or phenyl(1-4C)alkyl, pyridinyl (1-4C)alkyl; or R12R13 in R12R13-amino(1-4C)alkylcarbonylamino can be bonded together with the nitrogen atom to which they are bonded into a (5-6C)heterocycloalkyl ring, having one or two nitrogen atoms, optionally substituted with hydroxy(1-4C)alkyl; R14, R15 independently denote H, (1-6C)alkyl, (1-6C)alkylcarbonyl, (1-4C)alkoxycarbonyl or pyridinyl(1-4C)alkyl, optionally substituted on the aromatic ring with one substitute selected from halogen; or R16 denotes (di)(1-4C)alkylamino(2-4C)alkyl, hydroxycarbonyl(1-4C)alkyl, (1-4C)alkoxycarbonyl(1-4C)alkyl, phenyl(1-4C)alkyl or pyridinyl(1-4C)alkyl; R17, R18 independently denote H, (1-6C)alkyl, thiophenyl(1-4C)alkyl; or R17R18 in R17R18-aminocarbonyl(1-4C)alkoxy can be bonded into a morpholine or piperazine ring, R19 denotes H or (1-6C)alkyl; R20R21 independently denote H, (1-6C)alkyl or (1-4C)alkoxy(1-4C)alkyl; or R20R21 in R20R21-aminosulphonyl can be bonded into a morpholine ring; X denotes O or N-R22; Y denotes CH2 or C(O); Z denotes CN or NO2; R22 denotes H; R23, R24 independently denotes H; (1-4C)alkyl; or R23R24 in R23R24-aminocarbonyl can be bonded into a dihydropyridine ring; provided that compounds of formula I, in which X denotes O, R4 denotes phenyl and R7 is selected from H, (1-4C)alkylthio, (1-4C)alkylsulphonyl, R23-oxycarbonyl, and R23R24-aminocarbonyl, and compounds of formula I, in which X denotes O, R4 denotes (2-5C)heteroaryl and R7 denotes H are excluded. The invention also relates to use of 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives to prepare a medicinal agent for treating sterility.
EFFECT: improved useful biological properties.
12 cl, 73 ex
SUBSTANCE: invention refers to a compound of formula I where A represents an optionally substituted aryl or heteroaryl, B - a benzene or thiophene cycle, C - a benzene or aliphatic hydrocarbon cycle, while values of other radicals are disclosed in the description. The compound according to the present invention, and the based pharmaceutical compositions exhibit a strong antagonistic effect in relation to GnRH receptor that makes them applicable for treatment of GnRH-related diseases, particularly prostate cancer, benign prostatic hyperplasia, breast cancer, endometriosis and/or uterine fibroid tumour.
EFFECT: improved clinical effectiveness.
11 cl, 70 tbl, 765 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to 2-methyl-4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinoline derivatives of formula 1 , in which R1 represents (1-6C)alkyl; R2 represents halogen; R3 represents SO2NR5R6 or (1-4C)alkoxy; X represents O or NR7; R4 represents R8-(2-8C)alkyl, R8-(3-8C)alkenyl or R8-(2-4C)alkoxy-(2-4C)alkyl; Z represents CN or NO2; R5 and R6 independently on each other represent H or (1-4C)alkyl; or R5 together with R6 and N, to which they are bound, form 5-6-member saturated ring, optionally containing additional heteroatom, selected from O; R8 represents OH, (1-4C)alkoxy, NH2; NR9C(O)R11, NR9SO2R11 or C(O)NR9R10; R7 and R9 independently represent H or (1-4C)alkyl; R10 represents (1-4C)alkyl; R11 represents (1-4C)alkyl, (1-4C)alkoxy(1-4C)alkyl, (3-6C)cycloalkyl, (1-4C)alkoxy or phenyl, or (4-5C)heteroaryl, and (4-5C)heteroaryl stands for aromatic group, which has 4-5 carbon atoms and at least one heteroatom, selected from N and O; or to their pharmaceutically acceptable salts. Invention also relates to pharmaceutical composition, as well as to application of 2-methyl-4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinoline derivatives.
EFFECT: obtaining novel biologically active compounds, possessing agonistic activity with respect to FSH receptor.
8 cl, 33 ex
SUBSTANCE: invention refers to a composition containing encapsulated triterpenic acid: betulinic acid, ursolic acid or derivatives thereof in the form of salts and esters, or triterpene alcohol - betulin, which may be used in medicine for treating and preventing viral infections caused by DNA and RNA-containing viruses, such as influenza viruses, oncogenic viruses, herpes virus, herpes zoster virus, as well as infections caused by gram-positive and gram-negative bacteria: Staphylococcus spp., Streptococcus spp., Enterococcus spp., Shigella spp., Escherichia spp., Salmonella spp., Proteus spp., Acinetobacter spp., Citrobacter spp., Pseudomonas spp., Serratia spp., Klebsiella spp., Antracoides spp., Cryptococcus spp., pathogenic fungi of the genus Microsporum, Trichophyton, Nocardia, Aspergillus, yeast-like fungi of the genus Candida, including multiresistant strains, as well as Actinomycetes and some pathogenic protozoa: Entamoeba histolytica, Trichomonas vaginalis. The invention presents the composition containing an active ingredient presented by 0.5 wt % of betulin or 0.5 wt % of encapsulated triterpenic acid: betulinic acid, ursolic acid or derivatives thereof in the form of salts and esters and others, and carriers presented by: β-cyclodextrins, fullerene, lecithins and polymers binding to the ingredients to form ingredient-carrier complexes, and excipients.
EFFECT: higher efficacy of using the composition.
SUBSTANCE: invention relates to field of food industry, biotechnology and deals with antibacterial composition and strain of bacteriophage Escherichia coli, used for obtaining said composition. Characterised composition includes filtrate of Escherichia coli phage lysate, obtained with application of strain of bacteriophage Escherichia coli, deposited in collection of museum of microorganisms of Federal Budget Institution of Science "State Research Centre for Applied Microbiology and Biotechnology" of the Federal Service on Customers' Rights Protection and Human Well-being Surveillance (FBIS SRC AMB of Rospotrebnadzor) under number Ph 64, filtrate of Escherichia coli phage lysate, containing coli bacteriophage, filtrate of staphylococcus phage lysate, filtrate of salmonella phage lysate, filtrate of Listeria monocyctogenes phage lysate and target additives in amount 1.0÷95.0 wt % of composition weight.
EFFECT: claimed composition has required spectrum of specific activity due to inclusion of polyvalent bacteriophage and can be used in production of biologically active additives and food additives.
11 cl, 1 tbl, 13 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to pharmacology and medicine and concerns using a dipeptide of a general formula Tyr-Pro-X, where X - OH, NH2, OCH3, OC2H5, as an anti-inflammatory, antibacterial, wound-healing, regenerative, analgesic and burntreating agent for external application, as well as a dosage form for external application containing this dipeptide.
EFFECT: group of inventions provides preparing the effective agent for external applications with no side effects.
3 cl, 1 tbl, 22 ex
SUBSTANCE: composition contains the bactericidal substance Poviargol in the amount of 2.1-7.0 wt % and zosterin in the amount of 1.1-7.0 wt %.
EFFECT: synergetic action of the ingredients of the composition and promotion of the anti-inflammatory, radio protective, reparative action.
FIELD: veterinary medicine.
SUBSTANCE: kobaktan is administered intramuscularly at a dose of 2 ml per 50 kg of body weight daily for 7 days, glutoxim is administered subcutaneously at a dose of 3 mg per 1 kg of body weight once in 2 days in an amount of 10 injections, and also 1-3 sessions of hemosorption is carried out with the interval of 24-48 hours.
EFFECT: method enables to improve the efficiency of treatment while reducing mortality due to suppression of microbial factor, neutralisation and elimination of toxins from the body, normalisation of functional disorders.
1 tbl, 1 ex
SUBSTANCE: what is used is a targeted transport of antibacterial drugs to an area of inflammation by a single use of an extracorporeal antibiotic therapy including the antibiogram findings. With underlying intraoperative autologous blood donation combined with hypervolemic haemodilution and neuraxial anaesthesia, the infusion is followed by an autologous blood exfusion in a volume of 5-10 ml/kg of body weight with the total volume of the infusion dominating over the volume of the autologous blood exfusion by 130-140%, with the autologous blood reinfusion following a surgical haemostasis.
EFFECT: invention reduces the postoperative inflammatory complications in high-risk groups, enables reducing a therapeutic dose and a frequency of administration of a drug, eliminating or reducing the amount of transfused blood components, avoiding an adverse effect on a foetus presented in the form of the newborn's microflora change and the appearance of antibiotic-resistant forms of pathogens.
SUBSTANCE: formed sorbent comprises a nanodispersed mesoporous carbon material in the form of cylinders of the diameter of 8-13 mm, the length of 50-80 mm, the thickness of an external wall of 2.2-3.0 mm with one round inner passage or six triangular passages with the thickness of passage partition of 1.1-1.2 mm. The above sorbent contains at least 99.5 wt % of carbon, no more than 0.15 wt % of ash, no more than 0.30 wt % of sulphur; it has the total porosity not less than 0.4 cm3/g, the specific BET absorption surface of 200-300 m2/g and the crushing strength not less than 50 kg/cm2. The group of inventions also refers to a method for making the above sorbent involving mixing of nanodispersed carbon with 0.2-3% aqueous polyethylene oxide in ratio 1.0-1.2 respectively, extrusion of the mixture, drying of the extrudate, keeping at 200°C in an inert medium, thermal treatment in the hydrocarbon medium and activation with water steam at 700-950°C, and further pneumohydromechamnical treatment and drying. What is also declared is a method for prevention of suppurative septic complications in obstetric patients with a risk of an infection, involving the uterine cavity sanitation by placing the above sorbent therein in a capron container.
EFFECT: group of inventions enables reducing a risk of developing endometrium and reducing the number of antibiotics used in the obstetric patients.
3 cl, 2 tbl, 10 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to compounds of formula (I), wherein R1 represents an alkoxy group or halogen; each U and V independently represents CH or N; "----" means a bond or is absent; W represents CH or N, or if "----" is absent, then W represents CH2 or NH, provided not all U, V and W represent N; A represents a bond or CH2; R2 represents H, or provided A means CH2, then it also can represent OH; each m and n are independently equal to 0 or 1; D represents CH2 or a bond; G represents a phenyl group that is single or double substituted in meta- and/or para-position(s) by substitutes specified in alkyl, C1-3alkoxy group and halogen, or G represents one of the groups G1 and G2: wherein each Z1, Z2 and Z3 represents CH; and X represents N or CH and Q represents O or S; it should be noted that provided each m and n are equal to 0, then A represents CH2; or a pharmaceutically acceptable salt of such compound. Besides, the invention refers to a pharmaceutical composition for treating a bacterial infection containing an active ingredient presented by a compound of formula (I) or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert additive.
EFFECT: preparing the oxazolidine compounds applicable for preparing a drug for treating and preventing the bacterial infections.
14 cl, 8 dwg, 2 tbl, 33 ex
SUBSTANCE: present invention relates to a pharmaceutical salt of 8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-1-cyclopropyl-4-oxo-1,4-dihydro-3-quinoline carboxylic acid, characterised by that it is in form of a hydrochloride monohydrate and by solubility of at least 0.050 mg/ml water. The invention also relates to a pharmaceutical composition based on said pharmaceutical salt, use of said pharmaceutical salt and a method of treating or preventing bacterial infections based on use of said pharmaceutical salt.
EFFECT: obtaining a novel pharmaceutical salt of 8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-1-cyclopropyl-4-oxo-1,4-dihydro-3-quinoline carboxylic acid, characterised by good solubility in water, which influences bioavailability of the active ingredient.
7 cl, 16 dwg, 2 tbl, 9 ex
SUBSTANCE: feeding a medical solution is combined with an exposure to low-frequency ultrasound generated by a low-frequency ultrasonic cavitator that is AUZKh-100 PHOTEK apparatus. The medical solution is presented by a solution of metrogyl and dioxydine in ratio 5:1 or 1:1 respectively. The exposure involves feeding the solution at 0.2-0.5 ml/s. The cavitator is placed at 0.2-0.5 cm from a defect surface. First, the defect is exposed to an average-density ultrasonic flow of power 1.6-3 Wt/cm2 for 1-2 min. Then, the exposure is characterised by average-density ultrasonic power 3.1-8 Wt/cm2 for 4-10 min. The therapeutic course is 3-15 sessions every second day.
EFFECT: method provides the maximum mechanical debridement of the purulent-fibrinous impositions and the qualitative wound disinfection ensured by selecting the cavitation mode for specific drug preparations and deep penetration of the above drug preparations into the lesion.
3 cl, 1 ex
SUBSTANCE: method of treating periodontitis provides professional hygienic oral cleansing, antiseptic therapy, local drug-induced therapy. The local drug-induced therapy is two-staged with the use of zeolite-containing fossil flour with particle size of 0.3-0.4 mm. The first stage involves gingival infriction of a mixture consisting of zeolite-containing fossil flour and distilled water taken in equal weight parts for 10-15 min; the second stage includes applications of tampons impregnated with a mixture containing 2.5-3 weight parts of fossil flour and 1-1.5 weight parts of distilled water on the affected gingiva; the length of the local drug-induced therapy is 12-14 days.
EFFECT: effective treatment of periodontitis enables stable reduction of periodontal inflammation, fastening the remission time and reducing the number of aggravations.
2 tbl, 4 ex